WASHINGTON — A new report on cannabidiol, or CBD, from the Food and Drug Administration, does little to clarify the agency’s rules for the hemp-derived product.
Companies hoping to put the marijuana-adjacent product in dietary supplements and cosmetic products have long complained that the FDA’s rules are not clear enough to justify their investment in the industry. The latest report, sent to Congress this week, does little to clear that up — it just says the agency is still “evaluating” its policies on the issue.
Right now, although the FDA has said CBD can only be sold as a prescription drug, it has chosen not to go after the vast majority of companies selling CBD dietary supplements and cosmetic products. But it never formally codified any protections for those industries.